drugset / Trial / NCT06188208
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Timeline
- Start
- 2024-01-05
- Primary completion
- 2026-02-20
- Completion
- 2026-02-20
Outcome
Outcome not reported
Stopped: “The study has ended”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | VVD-130850 | Unknown | — | Oral |